

Expert insights on emerging evidence in SMA treatment

Faculty

Julie A. Parsons, MD, Habersfeld Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology, University of Colorado School of
Medicine, Aurora, CO, USA

Aravindhyan Veerapandiyan, MD, Associate Professor of Pediatrics, University of
Arkansas for Medical Sciences (UAMS) College of Medicine, Arkansas
Children's Hospital, Little Rock, AR, USA

Release date: May 2024

Expiration date: May 2025

Estimated time to completion: 0.5 hour

Available CME credits: 0.5 AMA PRA Category 1 Credit(s)[™]

Activity description

This highly engaging on-demand roundtable discussion webcast with two expert specialists (neurologists) will be designed around three discussions, some of which will be based on patient cases or potential case scenarios highlighting the importance of individualized care in spinal muscular atrophy (SMA), special considerations for treatments in practice, and emerging treatment options. The audience will be encouraged to test their knowledge and take part in making key clinical decisions to solve the patient-case challenges by participating in the embedded quizzes. The experts will provide practical guidance on a wide range of SMA treatments, from current options to emerging therapies. They will explore clinical evidence, real-world data, and case scenarios, addressing key topics in SMA care and decision-making factors.

Target audience

This activity is intended for US neurologists, pediatric neurologists, neuromuscular disease specialists, and other healthcare professionals (HCPs) involved in the management of SMA.

Educational objectives

After completing this activity, the participant should be better able to:

- **Evaluate** the clinical evidence on current and emerging treatments for SMA across the patient spectrum
- **Develop** individualized treatment plans for patients with SMA based on the latest evidence, and discuss treatment considerations throughout the patient journey
- **Discuss** ongoing developments in SMA treatment, including the potential of treatment sequencing and combinations

Joint accreditation statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Ology Medical Education. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physician continuing medical education

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period May 2024, through May 2025:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Take the pre-activity test
3. View the webcast
4. Take the post-activity test and complete the evaluation
5. Download the certificate of CME credit

Disclosure of conflicts of interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare, not a specific proprietary business interest of a commercial interest.

Faculty	Relationship identified with:
Julie Parsons, MD	Grant/Research support: Biogen, Biohaven, Novartis, PTC Therapeutics, Scholar Rock

	Consultant/Advisory Board: Biogen, Scholar Rock
Aravindhyan Veerapandiyan, MD	Employee/Owner: Arkansas Children's Hospital Grant/Research Support: AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, REGENXBIO, Sarepta Therapeutics Inc. Consultant/Advisory Board: AMO Pharma, AveXis, Biogen, Catalyst, Edgewise Therapeutics, FibroGen, Italfarmaco, Novartis, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Inc., Scholar Rock, UCB Pharma

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Jointly provided by PIM and Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Biogen MA, Inc.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient

management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's condition and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

Mehdi Attia, Medical Communications Manager
info@ologyeducation.org, www.ologyeducation.org

Chantel Crowl, Program Manager
inquiries@pimed.com, www.pimed.com

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Media

Internet